Earnings ·
Fate Therapeutics reports Q3 net loss of $0.25 per share and secures $15M CIRM grant
FATEFate Therapeutics Inc
Fate Therapeutics reported a third-quarter 2026 net loss of $30.7 million, or $0.25 per share, compared to a $32.3 million loss in the prior year period. Total operating expenses decreased by 12% to $32.2 million, driven by reductions in research and development and general and administrative costs. The company ended the quarter with $139.1 million in cash, cash equivalents, and investments, extending its cash runway to mid-2028. Additionally, Fate Therapeutics was awarded a $15.0 million grant from the California Institute for Regenerative Medicine (CIRM) to support clinical development of its RECLAIM-LN trial. The company is advancing FT819 in lupus nephritis and FT839 in autoimmune diseases using iPSC-derived cell therapies.